What are my alternatives to knee replacement?
Compare nonsurgical knee arthritis care, injection choices, and selected surgical alternatives—with evidence, limits, and questions for your clinician.
Read the guide ↗Medically reviewed by Charles A. DeCook, MD ·
← All optionsSpecialist review
Nerve freezing / iovera°
Target pain signals with cold. Relief is temporary.
Who might it suit?
For: Selected knee pain, or a discussion with your surgical team about pain control around knee replacement.
Not for: People with cold hypersensitivity or open or infected wounds near the treatment site; other contraindications require clinician screening.
Limits and important cautions
The studies used different protocols and follow-up times. Knee OA pain evidence should not automatically be applied to surgical recovery or permanent pain relief.
What happens, how long, and what could it cost?
- What happens
- A trained clinician uses controlled cooling to treat selected peripheral nerves.
- When might I notice a change?
- A reliable personal timeline cannot be predicted from the evidence reviewed here. Agree on a review date before starting.
- How long might benefit last?
- The intended pain interruption is temporary, not permanent joint repair.
- Repeat treatment
- Ask how response is assessed and what evidence supports repeat treatment for your indication.
- Activity and recovery
- Ask who provides follow-up, what symptoms need urgent attention, and what restrictions apply to you.
- Ask for a complete estimate
- Evaluation, procedure, device-related charges, and follow-up.
Use this as a consultation guide. A timeline is not a guarantee; the evidence and FDA sections below remain part of the decision.
THE EVIDENCE IN CONTEXT
Mixed sham-controlled trial results
Read the 3 selected references
- Radnovich et al.: cryoneurolysis for knee OA ↗
Found benefit at the primary 30-day endpoint in mild-to-moderate knee OA; one nerve target and device protocol were studied.
- Cryoneurolysis for chronic knee OA pain ↗
No significant benefit at the primary 14-day endpoint with the tested protocol. This was not an identical replication of the earlier trial.
- Genicular nerve interventions: randomized-trial synthesis ↗
Sham comparisons suggested modest short-term RFA benefit, with low-to-very-low certainty and no sustained benefit at later measured time points.
FDA status
FDA-cleared · knee OA painThe iovera° system’s FDA 510(k) clearance includes relief of knee osteoarthritis pain and symptoms for up to 90 days. This is device clearance for pain relief, not approval for cartilage repair. Benefit and duration vary; exact device configuration and labeling matter.
Site summary of FDA information · reviewed September 19, 2026. Refer to current product labeling. This is not an FDA endorsement of this site.What do professional guidelines say?
ACR: The conditional recommendation for radiofrequency ablation should not be treated as a recommendation for cryoneurolysis.
Will Medicare cover it?
UNSURE for your plan. Coverage depends on the procedure, indication, and local policy; obtain written confirmation.